+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Pneumococcal Vaccines: Epidemiology Forecast to 2028

  • ID: 4898064
  • Report
  • November 2019
  • Region: Global
  • 37 pages
  • GlobalData
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 2
Pneumococcal Vaccines: Epidemiology Forecast to 2028

Summary

Pneumococcal Vaccination rates in children are expected to remain steady at approximately 85% in the combined seven major markets (7MM - The US, France, Germany, Italy, Spain, the UK and Japan) by 2028, while vaccination rates in the elderly are expected to slightly increase to only 62% in the combined six major markets (6MM - The US, Germany, Italy, Spain, the UK and Japan) by 2028.

Streptococcus pneumoniae (S. pneumoniae) is a bacterial organism that causes a number of diseases, ranging from serious to mild infections. Symptoms depend on the part of the body that is infected, and range from fever, chills, and difficulty breathing to stiff neck and confusion. Transmission of S. pneumoniae primarily occurs through respiratory droplets. The term invasive pneumococcal disease (IPD) refers to more severe infections in which the bacterium is isolated from normally sterile sites. IPD is most common in high-risk groups, such as young children and the elderly, where the immune system is more vulnerable.

With pediatric pneumococcal vaccination, the primary reason for non-vaccination is vaccine hesitancy. In contrast, with elderly vaccination, the primary reason for non-vaccination is a lack of awareness about the pneumococcal vaccine from both the patient and healthcare professional. While pediatric rates are promising, there is still room for improvement. Addressing vaccine hesitancy requires further investigation and analysis into specific social, behavioral and economic factors that play a role in whether or not an individual gets vaccinated.

Furthermore, to help overcome insufficient doctor-patient communication and knowledge about vaccines, incentives or certifications should be offered to doctors who remain up-to-date on national vaccine guidelines and who are properly trained in vaccine counseling. In the future, continued efforts should focus on carrying out a targeted, actionable, and effective country-specific approach to overcome vaccine hesitancy, increase vaccine awareness, and ultimately reduce invasive pneumococcal disease incidence worldwide.

The latest research report “Pneumococcal Vaccines: Epidemiology Forecast to 2028” provides an overview of the risk factors and global trends of pneumococcal vaccines in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). Epidemiologists have utilized comprehensive, country-specific pneumococcal vaccination rate data and IPD diagnosed incidence rate data from nationally representative public health surveillance systems and databases to arrive at a meaningful, in-depth epidemiological analysis and forecast. Moreover, epidemiologists have provided detailed dose- and age-specific pneumococcal vaccination rates that are dependent on the routine immunization requirements of each market within this report.

Scope
  • The Pneumococcal Vaccines Epidemiology Report provides an overview of the risk factors and global trends of pneumococcal vaccines in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
  • This report also includes a 10-year epidemiological forecast for the vaccinated pneumococcal population segmented by age (pediatric and elderly), and diagnosed incident cases of IPD segmented by age (0-4 years, 5-9 years, 10-19 years, and by 10-year age groups up to 80 years and older). Pneumococcal vaccine dosing and age groups included within the forecast were dependent on the routine immunization requirements in each market and the availability of vaccination data. In addition, the epidemiology model corresponding to this report provides IPD diagnosed incident cases segmented into the top ten most common IPD serotypes by age (pediatric and elderly).
  • The Pneumococcal Vaccines epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
Reasons to buy

The Pneumococcal Vaccines Epidemiology series will allow you to -
  • Develop business strategies by understanding the trends shaping and driving the global pneumococcal vaccines market.
  • Quantify patient populations in the global pneumococcal vaccines market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups that present the best opportunities for pneumococcal vaccine therapeutics in each of the markets covered.
  • Understand magnitude of the pneumococcal vaccines population by dose and age.
Note: Product cover images may vary from those shown
2 of 2
1 Pneumococcal Vaccines: Executive Summary
1.1 Related Reports
1.2 Upcoming Reports

2 Epidemiology
2.1 Disease Background
2.2 Risk Factors and Comorbidities
2.3 Global and Historical Trends
2.3.1 Pediatric and Elderly Pneumococcal Vaccination Rates
2.3.2 Diagnosed Incidence of Invasive Pneumococcal Disease (Cases per 100,000 Population)
2.4 Forecast Methodology
2.4.1 Sources
2.4.2 Sources Not Used
2.4.3 Forecast Assumptions and Methods
2.4.4 Pneumococcal Vaccination Rates in the Pediatric Population
2.4.5 Pneumococcal Vaccination Rates in the Elderly Population
2.4.6 Diagnosed Incident Cases of Invasive Pneumococcal Disease
2.5 Epidemiological Forecast for Pneumococcal Vaccines and Invasive Pneumococcal Disease (2018-2028)
2.5.1 Pneumococcal Vaccinated Pediatric Population
2.5.2 Pneumococcal Vaccinated Elderly Population
2.5.3 Diagnosed Incident Cases of IPD
2.5.4 Age-Specific Diagnosed Incident Cases of IPD
2.6 Discussion
2.6.1 Epidemiological Forecast Insight
2.6.2 Limitations of the Analysis
2.6.3 Strengths of the Analysis

3 Appendix
3.1 Bibliography
3.2 About the Authors
3.2.1 Epidemiologist
3.2.2 Reviewers
3.2.3 Global Director of Therapy Analysis and Epidemiology
3.2.4 Global Head and EVP of Healthcare Operations and Strategy
3.3 About the Author
3.4 Contact Us
3.5 Disclaimer

List of Tables
Table 1: Risk Factors and Comorbidities for Invasive Pneumococcal Disease
Table 2: Pediatric Pneumococcal Vaccination Rate Trends (%)
Table 3: Elderly Pneumococcal Vaccination Rate Trends (%)

List of Figures
Figure 1: 7MM, Pneumococcal Vaccinated Pediatric Population, Both Sexes, 2018 and 2028
Figure 2: 6MM, Pneumococcal Vaccinated Elderly Population, Both Sexes, 2018 and 2028
Figure 3: 7MM, Diagnosed Incident Cases of IPD, Both Sexes, All Ages, 2018 and 2028
Figure 4: 7MM, Diagnosed Incidence of IPD, Both Sexes, All Ages, 20082028
Figure 5: 7MM, Sources Used for the Pneumococcal Vaccinated Pediatric Population
Figure 6: 6MM, Sources Used for the Pneumococcal Vaccinated Elderly Population
Figure 7: 7MM, Sources Used for the Diagnosed Incident Cases of IPD
Figure 8: 7MM, Pneumococcal Vaccinated Pediatric Population, Both Sexes, 2018
Figure 9: 6MM, Pneumococcal Vaccinated Elderly Population, Both Sexes, 2018
Figure 10: 7MM, Diagnosed Incident Cases of IPD, Both Sexes, All Ages, 2018
Figure 11: 7MM, Age-Specific Diagnosed Incident Cases of IPD, Men and Women, 2018
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll